Overview

An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

PRIMARY: To determine whether pentoxifylline changes the self-reported measures of quality of life status, using measures of scores from double-blinded drug withdrawal and drug restart periods. SECONDARY: To measure the changes in monthly CD4 counts, fasting serum triglyceride levels, and weight; to assess the safety of pentoxifylline in HIV-infected persons.

Phase:

N/A

Details

Lead Sponsor:

Community Research Initiative of New England

Treatments:

Pentoxifylline